CoreValve, S.A. Announces that more than 500 High-risk Patients have been Treated with its ReValving(R) System for Percutaneous Aortic Valve Replacement (PAVR)

IRVINE, Calif.--(BUSINESS WIRE)--CoreValve ( announced today that the expanded clinical evaluation of its ReValvingĀ® System for percutaneous aortic valve replacement (PAVR) in high-risk patients with aortic stenosis is enrolling patients at 32 sites in 11 European countries. The ReValvingĀ® System procedures can be performed under local anesthesia, without the need for surgical cut-down/repair, and without hemodynamic support or artificially accelerating the heart rate.

Back to news